Literature DB >> 26873347

STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion.

Dagmar Gotthardt1, Eva M Putz1, Eva Grundschober1, Michaela Prchal-Murphy1, Elisabeth Straka1, Petra Kudweis1, Gerwin Heller2, Zsuzsanna Bago-Horvath3, Agnieszka Witalisz-Siepracka4, Abbarna A Cumaraswamy5, Patrick T Gunning5, Birgit Strobl4, Mathias Müller4, Richard Moriggl6, Christian Stockmann7, Veronika Sexl8.   

Abstract

UNLABELLED: Natural killer (NK) cells are tightly regulated by the JAK-STAT signaling pathway and cannot survive in the absence of STAT5. We now report that STAT5-deficient NK cells can be rescued by overexpression of BCL2. Our experiments define STAT5 as a master regulator of NK-cell proliferation and lytic functions. Although NK cells are generally responsible for killing tumor cells, the rescued STAT5-deficient NK cells promote tumor formation by producing enhanced levels of the angiogenic factor VEGFA. The importance of VEGFA produced by NK cells was verified by experiments with a conditional knockout of VEGFA in NK cells. We show that STAT5 normally represses the transcription of VEGFA in NK cells, in both mice and humans. These findings reveal that STAT5-directed therapies may have negative effects: In addition to impairing NK-cell-mediated tumor surveillance, they may even promote tumor growth by enhancing angiogenesis. SIGNIFICANCE: The importance of the immune system in effective cancer treatment is widely recognized. We show that the new signal interceptors targeting the JAK-STAT5 pathway may have dangerous side effects that must be taken into account in clinical trials: inhibiting JAK-STAT5 has the potential to promote tumor growth by enhancing NK-cell-mediated angiogenesis. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26873347     DOI: 10.1158/2159-8290.CD-15-0732

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  56 in total

Review 1.  Microenvironmental regulation of tumour angiogenesis.

Authors:  Michele De Palma; Daniela Biziato; Tatiana V Petrova
Journal:  Nat Rev Cancer       Date:  2017-07-14       Impact factor: 60.716

2.  It is a differentiation game: STAT5 in a new role.

Authors:  Barbara Maurer; Matthias Farlik; Veronika Sexl
Journal:  Cell Death Differ       Date:  2017-05-12       Impact factor: 15.828

3.  Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma.

Authors:  Bethany Mundy-Bosse; Nathan Denlinger; Eric McLaughlin; Nitin Chakravarti; Susan Hwang; Li Chen; Hsiaoyin Charlene Mao; David Kline; Youssef Youssef; Rebecca Kohnken; Dean Anthony Lee; Gerard Lozanski; Aharon G Freud; Pierluigi Porcu; Basem William; Michael A Caligiuri; Anjali Mishra
Journal:  Blood Adv       Date:  2018-08-14

Review 4.  Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells.

Authors:  Suresh Bugide; Radoslav Janostiak; Narendra Wajapeyee
Journal:  Trends Cancer       Date:  2018-07-03

5.  JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors.

Authors:  Emily A Irey; Chelsea M Lassiter; Nicholas J Brady; Pavlina Chuntova; Ying Wang; Todd P Knutson; Christine Henzler; Thomas S Chaffee; Rachel I Vogel; Andrew C Nelson; Michael A Farrar; Kathryn L Schwertfeger
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-30       Impact factor: 11.205

6.  Human signal transducer and activator of transcription 5b (STAT5b) mutation causes dysregulated human natural killer cell maturation and impaired lytic function.

Authors:  Alexander Vargas-Hernández; Agnieszka Witalisz-Siepracka; Michaela Prchal-Murphy; Klara Klein; Sanjana Mahapatra; Waleed Al-Herz; Emily M Mace; Alexandre F Carisey; Jordan S Orange; Veronika Sexl; Lisa R Forbes
Journal:  J Allergy Clin Immunol       Date:  2019-10-07       Impact factor: 10.793

7.  IL-17 constrains natural killer cell activity by restraining IL-15-driven cell maturation via SOCS3.

Authors:  Xuefu Wang; Rui Sun; Xiaolei Hao; Zhe-Xiong Lian; Haiming Wei; Zhigang Tian
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-12       Impact factor: 11.205

Review 8.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

9.  Maybe we don't know JAK?

Authors:  Luis J Schwarz; Justin M Balko
Journal:  Mol Cell Oncol       Date:  2016-05-31

Review 10.  Targeting glioblastoma-derived pericytes improves chemotherapeutic outcome.

Authors:  Daniel A P Guerra; Ana E Paiva; Isadora F G Sena; Patrick O Azevedo; Walison N Silva; Akiva Mintz; Alexander Birbrair
Journal:  Angiogenesis       Date:  2018-05-14       Impact factor: 9.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.